Skip to main content

Improving Quality of Skin Biopsy Testing for Small Fiber Neuropathy Part I: Developing Demographic Algorithms With Childhood Norms

In brief

A new skin-biopsy algorithm extends small-fiber neuropathy testing to children

In 448 healthy volunteers, including 71 under 20, skin nerve-fiber density fell sharply in childhood and then more gradually with age; the analysis also found effects of sex and race. The resulting algorithm provides pediatric and adult reference norms, potentially helping identify abnormal results in young patients, but broader consensus on standards is still needed.

Journal
Muscle & nerve (Q1)
Published
20 November 2026
Study design
Cross-sectional study
Evidence level
Level 3, Low (CEBM 3b)
Authors
Max M Klein, Gary Zirpoli, Heather Downs, Madeleine C Klein, Hang Lee, Anne Louise Oaklander
PMID
43059601
DOI
10.1002/mus.70444

Why clinicians should know about it

  • Picked for Pathology and Forensic Medicine (top studies of the week, 22 November 2026): Develops age-adjusted thresholds and harmonization for diagnostic skin biopsy

Abstract

INTRODUCTION/AIM: Methods for counting epidermal neurite density (END), an objective biomarker for small-fiber neuropathy, are standardized, but laboratories' diagnostic algorithms defining Normal/Abnormal thresholds vary, permitting conflicting interpretations. Most laboratories lack norms for people < 20 years, precluding biopsy testing for them, and reporting units vary. Here we analyze these issues and develop a diagnostic algorithm that addresses them. METHODS: From 2000 to 2019 we obtained skin punches from the standard lower-leg sites of consented, screened healthy volunteers, including children ≥ 8 years, and performed standard bright-field PGP9.5 immunohistochemistry to generate a large, diverse dataset to analyze potentially contributory demographic factors to END-variability. We also analyzed results from 31 external healthy-END datasets to identify areas of inter-lab variability and targets for harmonization. RESULTS: Our 448-person dataset included 71 participants < 20 years. Their initially superabundant ENDs declined steeply in youth and shallowly thereafter. Thirty-one longitudinal sets of repeat biopsies corroborated our cross-sectional findings. We computationally modeled our dataset's significant age, sex, and race effects with initially single, then piecewise linear, and later logarithmic-linear fits to age. Among comparator studies, 81% also identified age declines, 53% reported lower male ENDs, and six studies of nominal race yielded conflicting conclusions. DISCUSSION: This unified pediatric/adult algorithm enables testing for childhood small-fiber neuropathy and may reduce false-negative interpretations for young adults. We generated seven quality-improvement suggestions for updating and harmonizing nomenclature, measurement-units, and algorithms. Setting consensus standards for normative datasets and algorithms might improve the quality and interoperability of skin-biopsy confirmation of small-fiber neuropathy and raise confidence in the validity of test results.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.